Baxdrostat: First Approval

doi:10.1007/s40265-026-02373-3

2026-08-21

PRE

Hannah A. Blair *

DOI：10.1007/s40265-026-02373-3

原文链接

原文求助

摘要

En 中文

巴克多拉斯特（BAXFENDY™）是一种由阿斯利康开发的同类首创、高选择性和强效的醛固酮合成酶抑制剂，用于治疗高血压、慢性肾脏病（CKD）和原发性醛固酮增多症，以及预防心力衰竭。2026年5月15日，巴克多拉斯特在美国首次获批，用于与其他抗高血压药物联合治疗高血压，以降低成人患者的血压（BP），适用于那些其他药物控制不佳的患者。本文总结了巴克多拉斯特在开发过程中的重要里程碑，这些里程碑促成了其在高血压治疗方面的首次获批。

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

暂无机构信息

引用论文

Emergence of aldosterone synthase inhibitors for treatment of difficult to treat hypertension 醛固酮合成酶抑制剂的出现为难治性高血压的治疗提供新途径

Hypertension Research

IF4.6

2025-11-14

PREAI

Sungha Park

Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function

Clinical Pharmacology in Drug Development

IF0

2024-02-04

OAAI

Mason W. Freeman; Yuan‐Di Halvorsen; Mary Bond; Brian Murphy; Jonathan Isaacsohn

26-A-9902-ACC EFFECT OF BAXDROSTAT ON CORTISOL RESPONSIVENESS IN PARTICIPANTS WITH UNCONTROLLED HYPERTENSION: A PHASE II RANDOMIZED CONTROLLED TRIAL 26-A-9902-ACC 巴克德罗斯特对未控制高血压患者皮质醇反应性的影响：一项II期随机对照试验

JACC

IF0

2026-04-01

PREAI

Fisher,Naomi D.L.; Zhou,Wunan; Olsson,Daniel; Lihn,Aina; Li,Xingyu; Sadiq,Muhammad Waqas; Wilderäng,Ulrica; Perl,Shira; Williams,Bryan

Phase 2 trial of baxdrostat for treatment-resistant hypertension Baxdrostat的II期临床试验用于治疗难治性高血压

IF0

2023-02-02

PREAI

Mason W. Freeman; Yuan-Di Halvorsen; William Marshall; Mackenzie Pater; Jon Isaacsohn; Catherine Pearce; Brian Murphy; Nicholas Alp; Ajay Srivastava; Deepak L. Bhatt; Morris J. Brown

Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension 巴克德罗stat在未控制性和难治性高血压中的疗效与安全性

IF0

PREAI

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension Baxdrostat在慢性肾脏病（CKD）和未控制高血压患者中的疗效与安全性

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IF9.4

2025-09-01

OAAI

Dwyer, Jamie P.; Maklad, Noha; Vedin, Ola; Monyak, John; Myte, Robin; Chertow, Glenn M.; Heerspink, Hiddo J. L.; Little, Dustin J.

Baxdrostat and Aldosterone Synthase Inhibitors: A New Class for Treatment-resistant Hypertension 巴克德罗stat和醛固酮合成酶抑制剂：治疗抵抗性高血压的一个新类别

Cardiovascular Drugs and Therapy

IF3.1

2026-05-13

PREAI

Ahmar Jan Qureshi; Muhammad Riyyan Tariq Tagga; Abdul Qayum Khan

Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial Baxdrostat对耐药性高血压患者动态血压的影响（Bax24）：一项III期、随机、双盲、安慰剂对照试验

The Lancet

IF97.3

2026-03-05

OAAI

Michel Azizi; Jenifer M Brown; Jamie P Dwyer; John M Flack; Erica S W Jones; Raisa Kurlyandskaya; Hongjian Li; Filip Birve; Aina S Lihn; Shira Perl; Markus P Schlaich; Hirotaka Shibata; Ji-Guang Wang; Bryan Williams

Efficacy and safety of aldosterone synthase inhibitors for uncontrolled hypertension: a meta-analysis of randomized controlled trials and systematic review 醛固酮合成酶抑制剂治疗未控制高血压的疗效与安全性：一项随机对照试验的荟萃分析及系统评价

Frontiers in Pharmacology

IF4.8

2025-09-22

OAAI

Yifan Gao; Xu Mu; Xingxue Pang

Turcu, A.F.; Freeman, M.W.; Bancos, I.; Ben-Shlomo, A.; Hamidi, O.; Hamrahian, A.H.; Huang, W.; Kirschner, L.S.; Sam, R.; Mallappa, A.; et al. Phase 2a Study of Baxdrostat in Primary Aldosteronism. N. Engl. J. Med. 2025, 393, 515–518. [Google Scholar] [CrossRef] [PubMed]Turcu, A.F.; Freeman, M.W.; Bancos, I.; Ben-Shlomo, A.; Hamidi, O.; Hamrahian, A.H.; Huang, W.; Kirschner, L.S.; Sam, R.; Mallappa, A.; 等. Baxdrostat治疗原发性醛固酮增多症的2a期研究。N. Engl. J. Med. 2025, 393, 515–518. [Google Scholar] [CrossRef] [PubMed]

IF0

PREAI

查看更多内容